Visceral fat directly increases heart disease risk by driving atherogenic dyslipidemia, chronic inflammation, and insulin resistance. Unlike subcutaneous fat, it releases harmful cytokines into the portal circulation, accelerating atherosclerosis—even in individuals with normal BMI (Kolb, 2022; Jin et al., 2022)

Visceral fat is the most dangerous type of belly fat for heart disease.

• Normal BMI does not rule out high cardiovascular risk.

• TG/HDL ratio is a simple marker of visceral fat risk.

• Inflammation links visceral fat to heart disease.

Clinical pearls

1. The "Hidden Scale" (Waist-to-Height Ratio)

• Scientific Perspective: BMI fails to account for ectopic fat deposition. The waist-to-height ratio (WtHR > 0.5) is a superior predictor of cardiometabolic risk because it correlates more strongly with Visceral Adipose Tissue (VAT) volume measured by MRI, regardless of ethnicity.

• Your bathroom scale is a "liar" because it can't tell the difference between muscle, bone, and the dangerous fat wrapping around your organs. Keep your waist circumference to less than half your height. If you are 180 cm tall, your waist should be under 90 cm.

2. The "Portal Pipeline" (The Liver's First Look)

• Scientific Perspective: Visceral fat drains directly into the portal vein. This exposes the liver to high concentrations of non-esterified fatty acids (NEFA) and pro-inflammatory cytokines (IL-6, TNF-alpha), triggering hepatic insulin resistance and the overproduction of VLDL particles.

• Imagine visceral fat as a "leaky factory" located right upstream from your liver. It dumps "trash" (inflammatory chemicals) directly into the liver's blood supply, forcing the liver to pump out more bad cholesterol and sugar into your system.

3. The "Quality vs. Quantity" Lipid Gap (sdLDL)

• Scientific Perspective: Standard lipid panels measure LDL mass (LDL-C), but visceral obesity drives the production of small dense LDL (sdLDL). These particles have higher arterial wall penetration, a longer half-life, and increased susceptibility to oxidation, making them significantly more atherogenic than large, buoyant LDL.

• Not all "Bad Cholesterol" is the same. Large LDL is like a beach ball that bounces off your artery walls. Small, dense LDL (driven by belly fat) is like a bullet—it’s small enough to get stuck inside the wall, where it starts the fire that leads to a heart attack.

4. The TG/HDL Ratio as a "Metabolic Compass"

• Scientific Perspective: A TG/HDL ratio > 3.0 (in mg/dL) is a highly specific surrogate marker for insulin resistance and the presence of the Atherogenic Lipoprotein Phenotype. It reflects the CETP-mediated exchange that creates small, dense LDL and HDL particles.

• You don’t need a fancy test to see if your metabolism is struggling. Divide your Triglycerides by your HDL. If the number is over 3, your body is likely struggling to process energy, and your "good" cholesterol isn't strong enough to clean up the "bad" cholesterol.

5. Exercise as a "Surgical Tool" (Independent of Weight)

• Scientific Perspective: Myokines released during skeletal muscle contraction (specifically Irisin and IL-15) promote the "browning" of white adipose tissue and specifically target visceral fat for lipolysis. This occurs even in the absence of significant total body weight loss.

• Don't be discouraged if the scale doesn't move after a month of lifting weights. Exercise acts like "internal surgery"—it specifically burns the dangerous deep fat first, even if the "pinchable" fat on the outside stays the same. You are getting healthier on the inside before you look different on the outside.

Visceral Fat and Heart Disease: The Hidden Cardiovascular Risk

You step on the scale. The number looks reassuring. Your Body Mass Index falls within the “normal” range. By conventional standards, your heart disease risk should be low.

But what if the most dangerous fat in your body isn’t visible—and isn’t reflected in your weight at all?

Deep inside your abdomen lies visceral fat, a metabolically active tissue wrapped around your liver, pancreas, and intestines. Unlike the fat you can pinch under your skin, visceral fat behaves less like storage and more like a dysregulated endocrine organ, continuously releasing inflammatory cytokines and free fatty acids directly into the portal circulation (Kolb, 2022). This direct liver exposure triggers insulin resistance, accelerates lipid abnormalities, and initiates a cascade of metabolic dysfunction that silently damages your cardiovascular system.

Over the past decade, research has fundamentally reshaped our understanding of cardiovascular risk. It is no longer just the amount of fat that matters, but where that fat is stored. Large prospective cohort studies now show that cumulative exposure to visceral fat independently predicts cardiovascular disease, even in individuals with otherwise normal weight and traditional risk markers (Chen & Fang, 2026; Xu & Sun, 2026).

At the vascular level, visceral fat promotes a highly atherogenic environment—driving the formation of small dense LDL particles, increasing triglycerides, lowering HDL, and sustaining chronic low-grade inflammation (Jin et al., 2022; Guerreiro et al., 2022). Together, these processes accelerate atherosclerosis, the underlying cause of most heart attacks and strokes.

This is why a growing number of “healthy-weight” individuals are developing cardiometabolic disease—a phenomenon often described as “thin outside, fat inside” (TOFI).

Your weight may look normal. But your metabolic risk may be anything but.

Why BMI Is Not Enough: The TOFI Problem

Body Mass Index (BMI) remains the most widely used measure of obesity in clinical practice. But BMI has a fundamental flaw: it measures total weight relative to height, completely ignoring where fat is stored.

This gave rise to the concept of TOFI — Thin Outside, Fat Inside — people who appear lean by standard measures yet carry dangerous amounts of visceral fat. Sometimes called "metabolically obese normal weight" (MONW) individuals, these patients carry a disproportionately elevated risk of coronary artery disease, type 2 diabetes, and metabolic syndrome.

A 2025 study published in the European Journal of Preventive Cardiology (Makhmudova et al., 2025) examined visceral adipose tissue (VAT), aortic distensibility, and atherosclerotic cardiovascular risk across all BMI categories. The findings were striking: high visceral fat predicted impaired aortic distensibility and increased atherosclerotic risk even in individuals with normal BMI, confirming that the location of fat — not merely the total amount — is the critical cardiovascular variable.

This is why waist circumference and waist-to-height ratio (a ratio above 0.5 signals elevated risk) are far more clinically meaningful than BMI for assessing cardiovascular risk, particularly in South Asian populations where visceral fat accumulation tends to occur at lower body weights.

Visceral Fat as an Endocrine Organ: How It Attacks Your Heart

The reason visceral fat is so dangerous lies in its unique biology. Visceral adipose tissue is not inert storage. It is an active endocrine and immune organ that secretes a continuous flood of biologically active substances.

Healthy adipose tissue produces adiponectin — a protective hormone that improves insulin sensitivity and exerts anti-inflammatory and anti-atherosclerotic effects. In visceral obesity, adiponectin production falls sharply. Simultaneously, visceral fat dramatically upregulates:

• TNF-α (Tumour Necrosis Factor-alpha) — promotes insulin resistance and vascular inflammation

• IL-6 (Interleukin-6) — drives hepatic production of CRP and amplifies systemic inflammation

• Leptin — rises to pathological levels, causing leptin resistance and further promoting inflammation

• MCP-1 (Monocyte Chemoattractant Protein-1) — recruits immune cells into arterial walls

Critically, visceral fat drains directly into the portal circulation — the blood supply that flows straight to the liver. This means the liver is the first organ to receive the entire cytokine payload from visceral fat depots, driving hepatic insulin resistance and triggering massive overproduction of VLDL (very low-density lipoprotein) particles. This is the opening act of atherogenic dyslipidemia.

A 2022 review in BMC Medicine (Kolb, 2022) elegantly reframed this process, documenting the transition of visceral adipose tissue inflammation from an initially protective immune response into a chronically detrimental, tissue-damaging state that fuels cardiovascular pathology systemically.

The Road to Atherosclerosis: Step by Step

Atherosclerosis — the progressive hardening and narrowing of arteries — is the underlying process behind most heart attacks and strokes. Visceral fat accelerates every stage of this process.

Step 1: Endothelial Dysfunction

The endothelium is the thin inner lining of your blood vessels. It is fragile, extraordinarily important, and exquisitely sensitive to the inflammatory cytokines that visceral fat releases. Elevated TNF-α and IL-6 reduce the production of nitric oxide (NO) — the molecule that keeps blood vessels relaxed and open — while simultaneously generating reactive oxygen species (ROS) that damage the arterial wall. This is endothelial dysfunction: the very first step in atherosclerosis.

Step 2: LDL Retention and Oxidation

Once the endothelium is damaged, ApoB-containing lipoprotein particles — particularly small dense LDL (sdLDL) — penetrate the arterial wall and become trapped. There, they are oxidized by the prevailing inflammatory milieu into oxidized LDL (oxLDL), a highly inflammatory form of cholesterol.

Step 3: Foam Cell Formation

Immune cells (monocytes) are recruited to the site of inflammation, where they transform into macrophages and engulf the oxidized LDL particles, becoming bloated "foam cells." These foam cells accumulate into fatty streaks — the earliest visible lesions of atherosclerosis — which then progress into full atherosclerotic plaques.

Step 4: Plaque Instability and Rupture

Chronic inflammation — sustained by visceral fat's cytokine output — continues to weaken plaques by thinning the fibrous cap that keeps them stable. When an unstable plaque ruptures, it triggers the formation of a blood clot that can block a coronary artery completely. The result is an acute myocardial infarction — a heart attack.

A 2025 study in Communications Medicine (de Souza et al., 2025) provided direct imaging evidence for this pathway, demonstrating that both visceral adipose tissue volume and hepatic fat content were independent determinants of carotid artery atherosclerosis — a validated proxy for coronary artery disease — after adjusting for all conventional cardiovascular risk factors.

Atherogenic Dyslipidemia: The Lipid Signature of Visceral Fat

One of visceral fat's most dangerous cardiovascular contributions is through the lipid profile it creates. Rather than simply raising LDL cholesterol, visceral fat generates a far more complex and damaging lipid pattern called atherogenic dyslipidemia, characterised by three simultaneous abnormalities.

Small Dense LDL (sdLDL): The Most Dangerous LDL Particle

Standard LDL cholesterol tests measure the total amount of LDL in the blood. They do not distinguish between large, fluffy LDL particles (relatively less dangerous) and small, dense LDL (sdLDL) particles, which are far more atherogenic.

A comprehensive review by Jin et al. (2022) in Frontiers in Cardiovascular Medicine detailed why sdLDL is so dangerous: these particles are small enough to penetrate deeply into the arterial wall, they remain in circulation longer, they have a stronger affinity for binding to arterial proteoglycans, and they are more susceptible to oxidation. Visceral fat directly drives sdLDL production by stimulating hepatic VLDL overproduction, which then undergoes remodelling into sdLDL particles through the action of cholesteryl ester transfer protein (CETP) and hepatic lipase.

Elevated Triglycerides

Visceral fat has a dramatically elevated rate of lipolysis — it constantly releases fatty acids into the portal circulation. This hepatic fatty acid overload stimulates the liver to package and secrete large numbers of triglyceride-rich VLDL particles, raising fasting and post-meal triglyceride levels. Chronically elevated triglycerides are themselves an independent cardiovascular risk factor, and they additionally fuel sdLDL production.

Low HDL Cholesterol

High-density lipoprotein (HDL) cholesterol performs reverse cholesterol transport — collecting cholesterol from peripheral tissues and arterial walls and returning it to the liver for disposal. In visceral obesity, HDL levels fall and HDL quality deteriorates. The net effect is impaired cholesterol removal from atherosclerotic plaques, accelerating their growth.

TG/HDL Ratio: A Powerful Clinical Tool

The triglyceride-to-HDL cholesterol ratio (TG/HDL ratio) has emerged as one of the most practically useful markers of cardiometabolic risk available in routine blood testing. It serves as a surrogate marker for insulin resistance and sdLDL particle predominance.

A TG/HDL ratio above 3.0 (when measured in mg/dL) signals high cardiometabolic risk and is strongly associated with visceral adiposity, insulin resistance, and increased cardiovascular event rates. For patients and clinicians alike, this simple calculation from a standard lipid panel provides actionable information that standard cholesterol testing alone misses.

Inflammation: The Chronic Fire Connecting Visceral Fat and Your Heart

If atherogenic dyslipidemia is the fuel of cardiovascular disease, chronic low-grade inflammation is the spark. Visceral fat maintains a persistent state of systemic inflammation through the continuous release of pro-inflammatory cytokines, creating what researchers describe as a "para-inflammatory" state — not acute enough to cause obvious symptoms, but sustained enough to progressively damage blood vessels and drive plaque formation.

Key inflammatory biomarkers elevated in visceral obesity include:

• hs-CRP (high-sensitivity C-reactive protein) — the most clinically used marker of vascular inflammation

• IL-6 — the primary driver of hepatic CRP production and an independent cardiovascular risk predictor

• TNF-α — promotes insulin resistance and endothelial dysfunction simultaneously

• MCP-1 — facilitates monocyte recruitment into arterial walls

A 2022 review in the Journal of Obesity (Guerreiro et al., 2022) systematically explored how adipose tissue inflammation transitions from a physiological protective response into a chronic pathological state, with macrophage infiltration of adipose tissue and a shift from anti-inflammatory (M2) to pro-inflammatory (M1) macrophage polarization playing a central mechanistic role.

This sustained inflammatory activation also creates a pro-thrombotic state — elevated fibrinogen, PAI-1 (plasminogen activator inhibitor-1), and platelet reactivity — that increases the likelihood of dangerous blood clot formation should an atherosclerotic plaque rupture.

Visceral Fat, Insulin Resistance, and Cardiovascular Risk Amplification

Visceral fat and insulin resistance form a vicious, self-amplifying cycle that dramatically escalates cardiovascular risk. Visceral fat drives insulin resistance through multiple simultaneous mechanisms:

1. Hepatic insulin resistance via portal free fatty acid overload and cytokine exposure

2. Skeletal muscle insulin resistance via elevated circulating fatty acids and cytokines

3. Adiponectin deficiency — removing a key insulin-sensitising signal

The resulting hyperinsulinaemia (chronically elevated insulin levels) is itself cardiovascular harmful: it increases renal sodium retention (raising blood pressure), amplifies sympathetic nervous system activity (further elevating blood pressure and heart rate), and promotes vascular smooth muscle proliferation.

This explains why visceral fat sits at the heart of metabolic syndrome — the cluster of hypertension, dysglycaemia, atherogenic dyslipidemia, and abdominal obesity that multiplies cardiovascular risk far beyond the sum of its individual components.

The Clinical Evidence: What the Research Tells Us

The strongest evidence base linking visceral fat to cardiovascular outcomes comes from large prospective cohort studies using objective visceral fat measurements — increasingly including novel metabolic scoring tools that capture cumulative fat exposure over time.

He et al. (2024), publishing in Nutrition, Metabolism and Cardiovascular Diseases, followed a prospective cohort tracking the relationship between visceral adiposity and the trajectory of cardiometabolic diseases over time. The study's most important finding was that visceral adiposity was associated not only with the incidence but also with the developmental trajectory of cardiometabolic diseases — meaning higher visceral fat accelerated disease progression, not merely its onset.

Chen et al. (2026) examined the association between cumulative metabolic scores for visceral fat and cardiovascular disease risk in patients across cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3, using the CHARLS database — one of the most comprehensive longitudinal datasets of middle-aged and older Chinese adults. Their findings demonstrated a robust, graded relationship: as cumulative visceral fat exposure increased, cardiovascular disease risk rose in a dose-dependent fashion, even after adjusting for traditional risk factors.

Xu & Sun (2026) extended this work, examining visceral fat trajectories across two separate prospective cohorts. Their analysis confirmed that dynamic changes in visceral fat — not just its baseline level — are critical determinants of cardiovascular disease onset, reinforcing the clinical importance of tracking visceral fat trends over time rather than performing single-point measurements.

Extending beyond coronary artery disease, Li et al. (2026) published in Frontiers in Endocrinology, demonstrating that elevated metabolic scores for visceral fat were significantly and independently associated with peripheral arterial disease in hypertensive patients — confirming that visceral fat's vascular damage is systemic, affecting arteries throughout the body, not just the heart.

Special Clinical Scenarios: Who Is Most at Risk?

The TOFI Patient: Normal Weight, Hidden Danger

The TOFI (Thin Outside, Fat Inside) phenotype deserves particular clinical attention. These individuals — with normal BMI and apparently healthy body composition on visual examination — harbour excess visceral fat that standard assessments miss. Makhmudova et al. (2025) explicitly confirmed elevated atherosclerotic cardiovascular risk in this group across BMI categories, underscoring the importance of waist circumference measurement in every cardiovascular risk assessment, regardless of BMI.

Sarcopenic Obesity

The combination of low skeletal muscle mass with high visceral fat — sarcopenic obesity — creates a compound metabolic insult. Reduced muscle mass severely limits glucose disposal capacity, dramatically amplifying insulin resistance already driven by excess visceral fat.

Visceral Fat and Aging

Ageing is characterised by a progressive redistribution of body fat toward visceral depots, even in the absence of significant weight gain. Declining levels of testosterone, oestrogen, and growth hormone all promote this visceral fat accumulation with age. A landmark 2026 review in Nature Aging (Maeyens et al., 2026) comprehensively documented how visceral adiposity interacts with the biology of ageing to amplify cardiovascular and metabolic disease risk — establishing visceral fat as a central target in healthy ageing strategies.

Practical Risk Assessment: What You and Your Doctor Can Do Right Now

You do not need a CT scan or MRI to begin assessing your visceral fat risk. The following simple, evidence-based tools are available in any clinical setting — or even at home:

1. Waist Circumference

• Men: >94 cm (European); >90 cm (South Asian) — elevated risk

• Women: >80 cm — elevated risk

• South Asian populations accumulate cardiovascular risk at lower waist circumference thresholds than Western populations

2. Waist-to-Height Ratio

• Divide your waist circumference by your height (in the same units)

• A ratio above 0.5 indicates elevated cardiometabolic risk in most adult populations

3. TG/HDL Ratio (from a standard fasting lipid panel)

• Calculate: Triglycerides (mg/dL) ÷ HDL Cholesterol (mg/dL)

• Ratio >3.0: High cardiometabolic risk; likely sdLDL predominance; probable insulin resistance

4. Fasting Glucose and HbA1c — for early detection of insulin resistance and prediabetes

5. hs-CRP — for quantifying systemic vascular inflammation

When these simple measures raise concern, clinicians may proceed to DEXA body composition analysis or CT/MRI-based visceral fat quantification for more precise assessment and monitoring.

Therapeutic Strategies: Proven Ways to Reduce Your Risk

Lifestyle — The Most Powerful Medicine

Nutrition:

• A low-refined carbohydrate, high-protein diet reduces hepatic VLDL production, lowers triglycerides, and specifically targets visceral fat depots

• A Mediterranean-style dietary pattern — rich in olive oil, fish, legumes, vegetables, and whole grains — is associated with significant visceral fat reduction and cardiovascular risk reduction in clinical trials

• Eliminating ultra-processed foods and sugar-sweetened beverages targets the primary dietary drivers of ectopic and visceral fat accumulation

Exercise:

• Resistance training is the most insulin-sensitising form of exercise, directly improving glucose disposal capacity and reducing visceral adiposity

• High-Intensity Interval Training (HIIT) has strong evidence for preferential visceral fat reduction compared to moderate continuous exercise

• Zone 2 cardio (sustained moderate-intensity aerobic training) enhances mitochondrial fat oxidation capacity and supports long-term visceral fat management

Crucially, exercise reduces visceral fat independently of body weight loss — meaning even without significant scale changes, regular exercise is delivering measurable cardiovascular protection.

Pharmacological Approaches

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) have demonstrated significant visceral fat reduction in clinical trials, alongside substantial cardiovascular outcome benefits in high-risk populations

• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) provide cardiometabolic protection through mechanisms including visceral fat reduction, blood pressure lowering, and direct cardiac benefits

• Statins reduce LDL cholesterol and stabilise atherosclerotic plaques, addressing downstream cardiovascular risk even when visceral fat remains elevated

Timeline of Cardiometabolic Improvement

• 2–4 weeks:
  → Improved insulin sensitivity

• 2–3 months:
  → Reduction in triglycerides
  → Increase in HDL cholesterol
  → Decrease in hs-CRP (systemic inflammation)

• 6–12 months:
  → Measurable reduction in visceral fat

• 1–3 years:
  → Plaque stabilization
  → Potential partial regression of atherosclerosis

Visceral Fat and Heart Disease: An Editorial Perspective

• Visceral fat is not passive adiposity—it is a pathophysiological driver of cardiovascular disease.
  Unlike subcutaneous fat, visceral adipose tissue functions as a dysregulated endocrine organ, releasing pro-inflammatory cytokines and free fatty acids directly into the portal circulation, thereby initiating hepatic insulin resistance and atherogenic dyslipidemia.

• Fat distribution—not total body weight—is the dominant determinant of cardiometabolic risk.
  The “TOFI” (Thin Outside, Fat Inside) phenotype highlights a critical clinical gap where individuals with normal BMI harbor high visceral fat and remain underdiagnosed yet at elevated cardiovascular risk.

• Atherosclerosis begins early in visceral adiposity through endothelial dysfunction.
  Chronic exposure to TNF-α, IL-6, and oxidative stress reduces nitric oxide bioavailability, facilitating ApoB-containing lipoprotein retention and oxidation within the arterial wall.

• Atherogenic dyslipidemia is the biochemical signature of visceral fat.
  Elevated triglycerides, reduced HDL, and predominance of small dense LDL (sdLDL) collectively enhance plaque formation and instability.

• Advanced lipid markers provide superior risk stratification beyond standard lipid panels.

  • ApoB reflects total atherogenic particle number and correlates more strongly with cardiovascular events than LDL-C

  • Non-HDL cholesterol captures all ApoB-containing lipoproteins

  • Remnant cholesterol is increasingly recognized as a driver of residual inflammatory risk
    These markers are particularly valuable in patients with discordant LDL-C and metabolic risk profiles.

• Inflammation is the central integrator.
  Visceral fat sustains chronic low-grade inflammation, promoting plaque progression and a pro-thrombotic state.

• Insulin resistance amplifies cardiovascular injury.
  Hyperinsulinemia contributes to hypertension, endothelial dysfunction, and vascular remodeling.

• Clinical implication:
  Waist-based metrics, TG/HDL ratio, and advanced lipid profiling should be routinely integrated into cardiovascular risk assessment—especially in metabolically ambiguous patients.

Frequently Asked Questions (FAQs)

1. Does visceral fat directly cause heart disease?

Yes — visceral fat is now considered a causal driver, not merely a marker, of cardiovascular disease. Through chronic inflammation, atherogenic dyslipidemia, and endothelial dysfunction, visceral fat actively initiates and accelerates the atherosclerotic process that underlies most heart attacks and strokes.

2. Can I have heart disease risk with a normal BMI?

Absolutely. The TOFI (Thin Outside, Fat Inside) phenotype demonstrates that individuals with completely normal BMI can carry high levels of visceral fat and carry disproportionately elevated cardiovascular risk. This is why waist circumference and waist-to-height ratio are essential measurements alongside BMI in any cardiovascular risk assessment (Makhmudova et al., 2025).

3. What is small dense LDL (sdLDL) and why does it matter?

sdLDL is a subtype of LDL cholesterol that is smaller, denser, more oxidation-prone, and more capable of penetrating arterial walls than standard LDL particles. Visceral fat strongly promotes sdLDL production, and sdLDL particles are significantly more atherogenic than large LDL particles — a distinction invisible to standard LDL cholesterol testing (Jin et al., 2022).

4. What is the TG/HDL ratio and what does my result mean?

The TG/HDL ratio is calculated by dividing your fasting triglycerides by your HDL cholesterol (both in mg/dL). A ratio above 3.0 strongly suggests insulin resistance, sdLDL predominance, and elevated cardiometabolic risk. It is one of the most actionable cardiovascular risk markers available from a standard blood test.

5. How does visceral fat cause inflammation?

Visceral fat cells and the immune cells that infiltrate visceral fat tissue continuously secrete pro-inflammatory cytokines including TNF-α, IL-6, and MCP-1. This drives chronic systemic low-grade inflammation that damages the endothelium, promotes plaque formation, and creates a pro-thrombotic environment — all of which directly accelerate cardiovascular disease (Guerreiro et al., 2022; Kolb, 2022).

6. What is the fastest way to reduce visceral fat?

The evidence-based combination that most rapidly reduces visceral fat is: reducing refined carbohydrates and sugar-sweetened beverages (which directly suppresses hepatic VLDL production and visceral fat deposition), adding resistance training (which improves insulin sensitivity), and incorporating HIIT sessions (which have preferential visceral fat-reducing effects). Caloric deficit remains fundamental, but exercise reduces visceral fat even independent of total weight loss.

7. Does visceral fat worsen with age even without weight gain?

Yes. Ageing is associated with progressive redistribution of fat toward visceral depots — driven by declining sex hormones, growth hormone, and shifts in cortisol metabolism — even when total body weight remains stable. This makes visceral fat monitoring increasingly important with advancing age, and active lifestyle strategies become progressively more essential to maintain cardiometabolic health (Maeyens et al., 2026).

Practical Applications: Your Action Plan Starting Today

You do not need to wait for a specialist appointment to take meaningful action. Here is a structured, evidence-informed starting point:

This Week:

• Measure your waist circumference and calculate your waist-to-height ratio

• Request a fasting lipid panel and calculate your TG/HDL ratio

• Eliminate all sugar-sweetened beverages and ultra-processed snacks

This Month:

• Begin resistance training 2–3 times per week (bodyweight or gym-based)

• Add at least 2 HIIT sessions per week (20 minutes each is sufficient)

• Shift your diet toward a Mediterranean-style pattern — more fish, vegetables, olive oil, legumes; fewer refined carbohydrates

This Quarter:

• Book a cardiovascular risk review with your doctor — share your waist measurement and TG/HDL ratio

• If hs-CRP is elevated, discuss further assessment

• Track your waist circumference monthly as a simple proxy for visceral fat change

Long-Term (6–12 months):

• Consider advanced body composition assessment (DEXA or visceral fat scoring) if risk factors persist

• Work with your healthcare provider on individualised pharmacological options if lifestyle changes are insufficient

Author’s Note: A Clinical Perspective

As a clinician in internal medicine, one of the most consistent—and concerning—patterns I encounter is the underestimation of cardiovascular risk in patients who appear “metabolically healthy” based on conventional metrics. Normal BMI, acceptable total cholesterol, and absence of overt disease often create a false sense of security. Yet, when examined more closely, many of these individuals exhibit clear evidence of visceral adiposity, insulin resistance, and atherogenic dyslipidemia.

This disconnect highlights a critical limitation in traditional risk assessment models. In real-world clinical practice, cardiovascular disease rarely develops in isolation—it emerges from a complex interplay of fat distribution, metabolic dysfunction, and chronic inflammation. Visceral fat sits at the center of this network.

What makes visceral adiposity particularly important is not just its association with disease, but its causal role in driving pathophysiology—from hepatic insulin resistance and ApoB overproduction to endothelial dysfunction and plaque instability. These processes often begin years, even decades, before clinical events such as myocardial infarction or stroke.

From a practical standpoint, this shifts our focus from weight-centric care to metabolic-centric care. Simple tools—waist circumference, waist-to-height ratio, TG/HDL ratio, and where possible, ApoB—provide far greater insight into true cardiovascular risk than BMI alone.

Equally important is the recognition that visceral fat is modifiable. Targeted lifestyle interventions, particularly resistance training, structured aerobic exercise, and dietary carbohydrate quality, can produce meaningful improvements within months. When indicated, pharmacological therapies further enhance risk reduction.

The key clinical message is this:

Do not be reassured by normal weight alone. Assess metabolic health deeply, act early, and treat proactively.

This approach not only improves outcomes—it redefines prevention..

Your heart cannot see your scale. But it feels every gram of visceral fat you carry.

Take action today: measure, assess, and commit to the changes that science has confirmed will protect your cardiovascular health for decades to come

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individual circumstances vary, and treatment decisions should always be made in consultation with qualified healthcare professionals.

Related Articles

The #1 Diet Strategy to Reduce Visceral Fat According to Latest Research

Why Belly Fat Causes Insulin Resistance: Portal Theory Explained Simply

Visceral Fat vs Subcutaneous Fat: The Hidden Belly Fat Driving Diabetes and Heart Disease | DR T S DIDWAL

Obesity and Fatty Liver Disease: What Science Says About Risk and Health | DR T S DIDWAL

Intermittent Fasting: Metabolic Health Benefits and the Evidence on Longevity | DR T S DIDWAL

Activate Your Brown Fat: A New Pathway to Longevity and Metabolic Health | DR T S DIDWAL

References

Chen, Q., & Fang, H. (2026). Association between cumulative metabolic score for visceral fat and cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome stage 0–3 patients: A prospective cohort analysis based on CHARLS database. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-026-05801-0

de Souza, R. J., Pigeyre, M. E., Schulze, K. M., et al. (2025). Visceral adipose tissue and hepatic fat as determinants of carotid atherosclerosis. Communications Medicine, 5, 424. https://doi.org/10.1038/s43856-025-01123-y

Guerreiro, V. A., Carvalho, D., & Freitas, P. (2022). Obesity, adipose tissue, and inflammation answered in questions. Journal of Obesity, 2022, 2252516. https://doi.org/10.1155/2022/2252516

He, Q., Wang, Y., Feng, Z., Chu, J., Li, T., Hu, W., Chen, X., Han, Q., Sun, N., Liu, S., Sun, M., Sun, H., & Shen, Y. (2024). Visceral adiposity associated with incidence and development trajectory of cardiometabolic diseases: A prospective cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 34(5), 1235–1244. https://doi.org/10.1016/j.numecd.2023.11.006

Jin, X., Yang, S., Lu, J., & Wu, M. (2022). Small, dense low-density lipoprotein-cholesterol and atherosclerosis: Relationship and therapeutic strategies. Frontiers in Cardiovascular Medicine, 8, 804214. https://doi.org/10.3389/fcvm.2021.804214

Kolb, H. (2022). Obese visceral fat tissue inflammation: From protective to detrimental? BMC Medicine, 20, 494. https://doi.org/10.1186/s12916-022-02672-y

Li, S., Yan, C., Wu, M., Wang, T., Zhu, L., Yu, C., Zhang, W., Zhou, W., Bao, H., & Cheng, X. (2026). The metabolic score for visceral fat and risk of peripheral arterial disease in hypertension patients: A prospective cohort study. Frontiers in Endocrinology, 17, 1764481. https://doi.org/10.3389/fendo.2026.1764481

Maeyens, L. T., Nelson, J. F., & Zhao, S. (2026). Visceral adiposity, metabolic health and aging. Nature Aging, 6, 506–519. https://doi.org/10.1038/s43587-026-01076-4

Makhmudova, U., Wild, B., Williamson, A., Steinhagen-Thiessen, E., Langenberg, C., Eils, R., Landmesser, U., & Sannino, A. (2025). Visceral adipose tissue, aortic distensibility and atherosclerotic cardiovascular risk across body mass index categories. European Journal of Preventive Cardiology, zwaf447. https://doi.org/10.1093/eurjpc/zwaf447

Xu, L., & Sun, M. (2026). Correlations between the cumulative metabolic score for visceral fat and its dynamic trajectories with the onset of cardiovascular disease in middle-aged and older adults: Findings from two prospective cohorts. The Aging Male, 29(1). https://doi.org/10.1080/13685538.2026.2650602